本帖最后由 老马 于 2012-1-13 21:20 编辑 : Q: s$ F$ R/ J4 o! L
) D4 Z# Z6 s$ {4 g+ \
爱必妥和阿瓦斯丁的比较
2 e1 K' t9 Y/ K. M
/ o+ S4 i. H4 H( h! R1 U9 Nhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/% |# N1 F, P Q
1 S5 K: K8 @- [$ r- u( S
' u, a( x! K5 ?$ K( T) ?http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/( R1 D5 e5 a S4 o
==================================================
( h: @- `" W! X' ]$ N) v6 OOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)2 i& A" g6 E! u3 Q1 p3 r* U
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
& d. V/ x# m4 x1 B7 ^Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.6 q% ?# U/ L5 r: @$ J. u1 i
|